Chimerix Press Release – Chimerix Appoints Michelle Berrey Chief Medical Officer
RESEARCH TRIANGLE PARK, NC, November 12, 2012 — Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that Michelle Berrey, MD, MPH, has joined the company as Chief Medical Officer.
“We are delighted to have Michelle join our leadership team. Dr. Berrey is a seasoned drug developer who has established a strong track record in antivirals, in particular with nucleotide analogs. She joins Chimerix at an important time for the company as our lead compound, CMX001, advances into Phase 3 clinical testing,” said Kenneth I. Moch, Chimerix President and Chief Executive Officer. “Her extensive background in antiviral drug development will be invaluable to our already strong team.”
Prior to joining Chimerix, Dr. Berrey was Chief Medical Officer at Pharmasset, Inc. (NASDAQ: VRUS), a company that focused on the development of nucleotide analogs for the treatment of hepatitis C, from 1997 until its acquisition by Gilead Sciences, Inc. (NASDAQ: GILD) in January 2012. Dr. Berrey’s experience includes the design, early development, medical governance, clinical strategy and product life cycle management of antiviral products.
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.